StrongDecrease
Absolute cardiovascular risk reduction
Icosapent ethyl → Absolute cardiovascular risk reduction
Icosapent ethyl → Absolute cardiovascular risk reduction
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Icosapent ethyl reduces cardiovascular risk in patients with CKM syndrome
Key finding
Treatment with IPE compared with placebo was associated with significant reductions in the primary composite endpoint (HR, 0.55 [95% CI, 0.38, 0.78]; P=0.0009).
The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial demonstrated that Icosapent ethyl significantly reduced cardiovascular events compared to placebo.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Some Concerns bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Icosapent ethyl, Placebo
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
Primary composite endpoint
Comparator
Placebo
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial demonstrated that Icosapent ethyl significantly reduced cardiovascular events compared to placebo.
Clinical relevance
These findings are clinically significant as they suggest that Icosapent ethyl can effectively lower the risk of cardiovascular events, which is crucial for patients at high risk of heart disease. This could lead to improved treatment strategies and better health outcomes for individuals with cardiovascular risk factors.
Keep in mind
The study may have limited generalizability due to specific population characteristics. Potential confounding factors were not fully accounted for. The long-term effects of Icosapent ethyl beyond the study period are unknown.
Published in
Journal Reference
Publication details and source links for this paper.
Michael M, Deepak LB, Eliot AB, et al. Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. American Journal of Preventive Cardiology. 2026;25:101387. doi:10.1016/j.ajpc.2025.101387
Save this study and add notes to your research library.
Main Effects
Icosapent ethyl significantly reduced the primary composite endpoint (HR, 0.55; P=0.0009).
No significant difference was found in the placebo group for the primary composite endpoint (HR, 1.44; P=0.02).
Icosapent ethyl significantly reduced the key secondary composite endpoint (HR, 0.52; P=0.002).
An absolute risk reduction of 11.2% was observed with Icosapent ethyl.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Icosapent ethyl and Absolute cardiovascular risk reduction, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), Major adverse cardiovascular events, 5-point composite.
This study contributes evidence to
Primary intervention
Icosapent ethyl
Primary outcomes
- Absolute cardiovascular risk reduction
- Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
- Major adverse cardiovascular events, 5-point composite
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
3
Evidence pairs
3
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 63
1
Related topics
3
Evidence pairs
33
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 3 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Icosapent ethyl → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Icosapent ethyl → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
StrongDecrease
Major adverse cardiovascular events, 5-point composite
Icosapent ethyl → Major adverse cardiovascular events, 5-point composite
Icosapent ethyl → Major adverse cardiovascular events, 5-point composite
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Icosapent ethyl reduced cardiovascular events significantly (HR, 0.55; P=0.0009).
- Key secondary endpoints also showed significant reductions (HR, 0.52; P=0.002).
- An absolute risk reduction of 11.2% was noted with a number needed to treat of 9.
Who this applies to
- Adults at high risk for cardiovascular events.
- Individuals with a history of cardiovascular disease or risk factors.
Keep in Mind
- Results may not apply to populations outside the study's demographics.
- The study's findings are based on a specific duration and may not reflect long-term outcomes.
- Further research is needed to confirm the findings and explore long-term effects.
Between the Lines
- The study may have limited generalizability due to specific population characteristics.
- Potential confounding factors were not fully accounted for.
- The long-term effects of Icosapent ethyl beyond the study period are unknown.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Icosapent ethyl and Absolute cardiovascular risk reduction, Icosapent ethyl and Cardiovascular Outcomes.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Absolute cardiovascular risk reduction Evidence Hub
All studies measuring Absolute cardiovascular risk reduction
1 studies
outcome_hubMeasures Absolute cardiovascular risk reduction as a key outcome.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
1 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
Icosapent ethyl Evidence Hub
All studies on Icosapent ethyl
1 studies
intervention_hubContributes to Icosapent ethyl evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Icosapent ethyl and Absolute cardiovascular risk reduction
Intervention: Icosapent ethylOutcome: Absolute cardiovascular risk reduction
1 results
All studies on Icosapent ethyl and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Intervention: Icosapent ethylOutcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
1 results
All studies on Icosapent ethyl
Intervention: Icosapent ethyl
1 results
All studies measuring Absolute cardiovascular risk reduction
Outcome: Absolute cardiovascular risk reduction
1 results
All studies measuring Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
Outcome: Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Icosapent ethyl improve absolute cardiovascular risk reduction?
Emerging Evidence
Icosapent ethyl appears to improve Absolute cardiovascular risk reduction.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Absolute cardiovascular risk reduction
EvidenceScore™ Emerging | EvidenceScore™ 55.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Icosapent ethyl improve composite cardiovascular events (cv death, mi, stroke, hf hospitalization)?
Emerging Evidence
Icosapent ethyl appears to improve Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Emerging | EvidenceScore™ 55.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Icosapent ethyl affect major adverse cardiovascular events, 5-point composite?
Emerging Evidence
Icosapent ethyl appears to improve Major adverse cardiovascular events, 5-point composite.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Major adverse cardiovascular events, 5-point composite
EvidenceScore™ Emerging | EvidenceScore™ 55.7 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
HbA1c mediates cardiovascular benefits of GLP-1 receptor agonistsIntensive glycemic control may lower cardiovascular events in some diabetes patientsTicagrelor monotherapy reduces bleeding in diabetic ACS patientsTighter glycaemic targets may reduce serious infant morbidityCanagliflozin reduces cardiovascular and kidney risks in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.